# Study to Assess LX201 for Prevention of Corneal Allograft Rejection or Graft Failure in Subjects Who Have Experienced One or More Rejection Episodes Following Penetrating Keratoplasty

> **NCT00447642** · PHASE3 · TERMINATED · sponsor: **Lux Biosciences, Inc.** · enrollment: 122 (actual)

## Conditions studied

- Corneal Transplantation
- Corneal Graft Rejection

## Interventions

- **DRUG:** LX201
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT00447642
- **Lead sponsor:** Lux Biosciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-04
- **Primary completion:** 2008-08
- **Final completion:** 2010-01
- **Target enrollment:** 122 (ACTUAL)
- **Why stopped:** The primary efficacy endpoint was not met
- **Last updated:** 2012-10-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00447642

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00447642, "Study to Assess LX201 for Prevention of Corneal Allograft Rejection or Graft Failure in Subjects Who Have Experienced One or More Rejection Episodes Following Penetrating Keratoplasty". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00447642. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*